Could a common diabetes drug help heal fatty liver?
NCT ID NCT06982378
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study looks at whether a GLP-1 receptor agonist, a drug already used for diabetes and obesity, can improve fat buildup in the liver and blood in people with MASLD. Researchers will measure changes in fats, proteins, and genes in 30 participants who already take the drug. The goal is to understand how the drug affects liver health at a molecular level.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GLP-1 receptor agonist
- What this could lead to
- If successful, this could show that GLP-1 receptor agonists improve liver fat and related metabolic issues in people with MASLD, pointing toward a better treatment approach.
- What could go wrong
- This is a small, early-stage study (30 people) that only looks at changes in lab markers, not long-term health outcomes. It may not prove the drug works for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?